Since breast cancer cells at the invasive front of a primary tumor tend to be mesenchymal (Kalluri and Weinberg, 2009) and breast CTCs have been found to express markers of EMT in addition to stem cell traits (Aktas et al., 2009; Bonnomet et al., 2010), it would seem a logical extension of the hypothesis that E-selectin ligands are upregulated with EMT and the corresponding CD44+/CD24- CSC phenotype. The gene discussed is CD44; the disease is breast carcinoma.